Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | unknown | Phase 2 | 30 | Xuanwu Hospital, BeijingOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT02304458 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas |
| completed |
| Phase 1 / Phase 2 |
| 140 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Oct 17, 2023 |
| clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02998983 | Racotumomab in Patients With High-risk Neuroblastoma | completed | Phase 2 | 39 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04758000 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse(Metform-Bone) | recruiting | Phase 2 | 67 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03595228 | BN Brachyury and Radiation in Chordoma | completed | Phase 2 | 29 | Bavarian NordicINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03110744 | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma(NCT-PMO-1601) | completed | Phase 2 | 43 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT03561259 | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects(OPTIMUM) | unknown | Phase 2 | 60 | Jubilant DraxImage Inc.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT02511132 | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma | completed | Phase 2 | 22 | Gradalis, Inc.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial(NB2013-HR) | terminated | Phase 2 | 3 | University of CologneOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03359005 | Irinotecan and Temozolomide for Ewing Sarcoma | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 5 | Oct 24, 2022 | clinicaltrials |
| NCT02727387 | Protocol for the Treatment of Metastatic Ewing Sarcoma(EW-2) | completed | Phase 2 | 155 | Italian Sarcoma GroupNETWORK | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | withdrawn | Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 4 | Sep 1, 2022 | clinicaltrials |
| NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | not yet recruiting | Phase 2 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT02035137 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat(N2011-01) | completed | Phase 2 | 114 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jun 8, 2022 | clinicaltrials |
| NCT03275818 | Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma(ABRADES) | completed | Phase 2 | 69 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT00072358 | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | completed | Phase 2 | 291 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01542736 | Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) | completed | Phase 2 | 8 | University of Colorado, DenverOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT05125666 | Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection | unknown | Phase 2 | 30 | Cairo UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03291080 | Oral Liquid 13-cis-retinoic Acid (13-CRA)(My-CRA) | completed | Phase 1 / Phase 2 | 20 | Nova Laboratories LimitedINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02743429 | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma | unknown | Phase 2 | 40 | University Medicine GreifswaldOTHER | 2 | Oct 4, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02596828 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | completed | Phase 2 | 4 | University of RegensburgOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects(CAPTIVE) | completed | Phase 2 | 49 | DNAtrix, Inc.INDUSTRY | 2 | Jul 15, 2021 | clinicaltrials |
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | terminated | Phase 2 | 4 | Jean M. Tersak, M.D.OTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Dec 4, 2023source: clinicaltrials